Globe Life Inc. (GL) Down 5.3% — Dump the Shares?
Globe Life Inc. (GL) is under heavy pressure this Friday, last trading at $159.45 on the NYSE, down $8.96 from the prior close of $168.41. The decline adds to a pullback that has been building for months. GL now trades roughly 16.8% below its 52-week high of $191.55, reached on July 17, 2026. Today's move has also pushed the stock beneath the $165 level that one prominent Wall Street firm now views as fair value.
Volume stands at approximately 274,975 shares with the session still open, compared with a 90-day average of roughly 569,900. That puts turnover at a little under half of a typical full day's activity at this point in the session.
Why Globe Life Inc. Price is Moving Lower
The selloff traces to Globe Life's Q3 results, released on October 21, and a sharp downgrade from Piper Sandler that followed on October 23. Operating EPS came in at $4.84, short of analyst estimates of roughly $4.90 to $4.91. GAAP EPS of $4.62 fell well below the reported $4.85 consensus. Revenue grew 5.5% year over year to $1.596 billion from $1.513 billion but missed the $1.61 billion estimate. Net income declined to $361.1 million from $387.8 million a year earlier. Operating EPS edged up only modestly from $4.81, which offered little cushion against the misses elsewhere.
The guidance cut weighed more heavily than the quarter itself. Management lowered its 2026 operating EPS outlook to a range of $15.35 to $15.65, down from the prior $15.55 to $15.95. The company cited an approximately $16 million underwriting loss at Evry Health and $7 million in excess Medicare Supplement claims tied to a processing delay at CMS. Neither item is large relative to a $12.94 billion market cap. Together, however, they introduce uncertainty into a business investors have traditionally valued for its predictability.
Piper Sandler sharpened that concern on Friday. The firm cut GL from Overweight to Neutral and lowered its price target from $200 to $165. It said the results raised questions about medical-claim severity, irregularity in Medicare claims, and the quality of 2027 guidance. Shares were already down 3.4% at $162.69 in premarket trading, and the decline deepened once the regular session opened. Insurers are broadly softer today, with MetLife, Inc. (MET) down 2.38% and Manulife Financial Corporation (MFC) down 2.21%. Even so, GL's 5.32% drop is more than double those moves, which marks this as a company-specific repricing rather than an industry-wide retreat.
What is the Globe Life Inc. Rating - Should I Sell?
Weiss Ratings assigns GL a B rating. Current recommendation is Buy. That rating holds up against today's decline because the earnings miss and guidance trim, while unwelcome, do not undermine the core profitability and balance sheet strength that anchor Globe Life's profile. The stock trades at a forward P/E of 11.18 against trailing EPS of $15.06. That multiple already reflects a measure of skepticism about the company's health-related lines.
The Excellent rating on the Efficiency Index is backed by a 20.95% ROE and a 19.57% profit margin. Those figures are notable for a life and supplemental health insurer serving middle-income households, where policy sizes are small and distribution costs run high. The Excellent Solvency Index rating reflects a balance sheet strong enough to absorb a $16 million underwriting loss and a $7 million claims timing issue without strain. The Good rating on the Growth Index fits 8.00% revenue growth, though the third quarter's 5.5% top-line increase suggests that pace is cooling. The Dividend Index is rated Good on the strength of a consistent payout. The 0.75% yield, however, is modest enough that income alone is not the primary case for owning the shares.
Where the picture becomes more nuanced is in market behavior. GL is rated Good on the Total Return Index, which reflects reasonable returns over the measurement period. A slide of nearly 17% from the July high shows how quickly those gains can erode. The Fair rating on the Volatility Index captures exactly the kind of session investors are seeing today. A guidance cut and an analyst downgrade can produce outsized single-day moves in a stock usually treated as a steady compounder, which is why the Volatility Index is not rated higher.
Within the Financials sector, Globe Life is on par with MetLife, Inc. (MET, B) and a notch above The Progressive Corporation (PGR, B-). It trails The Travelers Companies, Inc. (TRV, A+) and Manulife Financial Corporation (MFC, A+), both of which carry stronger risk/reward profiles in Weiss's framework.
About Globe Life Inc.
Globe Life Inc. (GL) is a Financials company operating in the Insurance industry. It specializes in life and supplemental health coverage for lower-middle and middle-income households across the United States. Headquartered in McKinney, Texas, and formerly known as Torchmark Corporation, the company sells basic protection products that larger insurers often underserve. These include whole and term life insurance, accidental death coverage, cancer and critical illness policies, and Medicare Supplement plans.
Distribution is the defining feature of Globe Life's model. The company relies heavily on exclusive captive agencies operating under brands such as American Income Life, Liberty National, and Family Heritage. American Income Life focuses on union and credit union members, while Family Heritage concentrates on supplemental health protection. The company also runs a sizable direct-to-consumer operation under the Globe Life brand, reaching customers through mail, digital, and phone channels. United American, an independent-agency arm, anchors much of the company's Medicare Supplement business.
Globe Life's competitive edge comes from its agency recruiting engine, its disciplined underwriting on small-face-value policies, and the long-duration nature of its life insurance reserves. Those reserves feed a large investment portfolio weighted toward fixed-income securities. This combination produces steady premium income and investment spread earnings. The health side of the business, particularly Medicare Supplement, carries more claims variability than the core life book, a sensitivity that came into sharp focus this quarter.
Investor Outlook
Globe Life Inc. (GL) carries a Weiss Rating of B (Buy), supported by excellent efficiency and solvency, but the guidance cut and Piper Sandler downgrade warrant a cautious near-term stance. Investors should watch whether Medicare Supplement claims normalize once the CMS processing delay clears, whether Evry Health's underwriting losses prove contained, and how management frames 2027 guidance given the questions it now faces. See full rankings of all B-rated Financials stocks inside the Weiss Stock Screener.
--